AUTHORS
Audrey Le Floc'h, PhD, Regis Peffault De Latour, MD, PhD2, Jong Wook Lee, MD3, Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP4, Hawk Kim, MD, PhD5, Jun Ho Jang6, Bhumika J Patel7, Sophia Rebecca Balderman, MD8, Jaroslaw P. Maciejewski, MD, PhD, FACP9, Antonio M. Risitano Jr, MD, PhD10, Emily Labriola-Tompkins11, Erica Chio12, Maria Matthaiakaki Panagiotaki13, Shane McCarthy14, Jamie M Orengo, PhD, MPH15, Lorah Perlee, PhD16, Thomas D Norton, MD17
AFFILIATIONS
1 Regeneron Pharmaceuticals, Tarrytown, New York, United States
2 Saint-Louis Hospital, Paris City university, French reference center for aplastic anemia and PNH, Paris, France
3 Hanyang University Seoul Hospital, Seoul, Korea, Rep. of South
4 Kings College Hospital, London, United Kingdom
5 Ewha Woman’s University Seoul Hospital, Ewha Woman’s University College of Medicine, Seoul, Korea, Rep. of South
6 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Rep. of South
7 Tausig Cancer Center, Cleveland Clinic, Cleveland, United States
8 Tausig Cancer Center, Cleveland Clinic, Cleveland, United States
9 Tausig Cancer Center, Cleveland Clinic, Cleveland, United States
10 A.O.R.N. 'SAN.G MOSCATI', Avellino, Italy
11 Regeneron Pharmaceuticals, Tarrytown, New York, United States
12 Regeneron Pharmaceuticals, Tarrytown, New York, United States
13 Regeneron Pharmaceuticals, Tarrytown, New York, United States
14 Regeneron Pharmaceuticals, Tarrytown, New York, United States
15 Regeneron Pharmaceuticals, Tarrytown, New York, United States
16 Regeneron Pharmaceuticals, Tarrytown, New York, United States
17 Regeneron Pharmaceuticals, Tarrytown, New York, United States
ABSTRACT
Introduction: Aplastic anemia (AA) is an autoimmune disorder in which cytotoxic lymphocytes destroy hematopoietic stem and progenitor cells, causing life-threatening cytopenias. For patients ineligible for transplantation, immunosuppressive therapy (IST) is standard of care, but current options carry significant toxicities and fail a substantial proportion of patients. Gamma chain (γc) cytokines signal through a shared receptor subunit, interleukin-2 receptor subunit gamma (IL2RG), to drive lymphocyte development and effector function, making IL2RG blockade a rational strategy for suppressing pathogenic lymphocytes in AA. REGN7257, a human monoclonal antibody targeting IL2RG, was evaluated in a first-in-human, phase 1, multinational, open-label, dose escalation study in patients with severe AA (SAA) refractory to or relapsed on prior IST. REGN7257 demonstrated an acceptable safety profile with evidence of pharmacodynamic activity suggesting potential clinical benefit. Here, we report longitudinal serum proteomic profiling to further characterize the pharmacodynamic (PD) effects of REGN7257.
Methods: This open-label study enrolled 17 participants with IST-refractory (n=11) and IST-relapsed (n=6) SAA across 4 countries (France, South Korea, the United Kingdom and the United States). The cohort comprised 10 female and 7 male participants, was predominantly Asian (52.9%), with a median age of 55.9 years, a median SAA duration of 9.6 years, and a median of 2 prior lines of therapy. Serum samples were collected before dosing (Day 1) and at Days 2, 4, 8, 15, 29, 90, 180, and 365 from participants receiving a single intravenous dose of REGN7257 across four dose levels (DL1, 5 mg/kg; DL2, 10 mg/kg; DL3, 20 mg/kg; DL4, 40 mg/kg). Serum proteomic analysis was performed using the Olink Explore 3072 platform. Enrichment of protein abundance in HALLMARK pathways was assessed by Gene Set Enrichment Analysis (GSEA). Protein levels were z-score normalized and clustered into functional modules. Dose levels were grouped (DL1+DL2 vs DL3+DL4) for PD comparison. Serum concentrations of selected proteins were confirmed by quantitative analysis using Meso Scale Discovery (MSD).
Results: GSEA of longitudinal serum Olink proteomic data from SAA patients following single-dose REGN7257 identified dose-dependent changes in circulating proteins relative to baseline. Specifically, REGN7257 induced dose-dependent reductions in allograft rejection scores (an immune-related Hallmark gene set from Molecular Signature Database) with distinct protein modules exhibiting concurrent but opposing temporal dynamics. The first proteins to emerge as leading-edge contributors to these changes were the γc cytokines IL2, IL7 and IL15 (Day 2), consistent with on-target inhibition of receptor-mediated cytokine clearance and confirmation of systemic target engagement. By Day 8, a markedly broader proteomic response was observed, with leading-edge proteins encompassing a cytotoxic T/NK effector module (e.g., KLRD1, NCR1, GZMA, GZMB, FASLG, CRTAM, CD7, CD8A, IFNG) and an interferon/antigen-presentation module (e.g., TAP1, CXCL9, IL12RB1, CD74, HLA-DRA, CXCL13), indicating progressive dampening of the autoreactive immune response. Proteomic changes were most pronounced during peak antibody exposure (Days 8-29) and returned toward baseline as the drug cleared from circulation. Dose-dependent increases in the γc cytokines IL2, IL7, and IL15, and concomitant decreases in the effector molecules IFNγ and Granzyme B, were confirmed by quantitative MSD analysis.
Conclusions: Longitudinal serum proteomic profiling from patients with IST-refractory or IST-relapsed SAA treated with REGN7257 demonstrated that single-dose administration achieved systemic IL2RG target engagement, evidenced by dose-dependent accumulation of γc cytokines. This was accompanied by attenuation of cytotoxic effector and interferon-driven immune signatures, suggesting that IL2RG blockade with REGN7257 inhibited the inflammatory pathways that are hallmarks of SAA pathobiology. These findings support continued clinical development of REGN7257 in SAA and highlight the potential utility of IL2RG blockade in diseases driven by activated T cells and NK cells.
DISCLOSURES
Audrey Le Floc'h, PhD: Regeneron Pharmaceuticals - Current equity holder in publicly-traded company; Regeneron Pharmaceuticals - Current Employment